Horizon Europe – MSCA Doctoral Networks
Partner organizations
Consortium partners
Universiteit Maastricht
(Maastricht, The Netherlands)
Coordinator
https://www.maastrichtuniversity.nl
​
Universiteit Maastricht is a research-intensive university with strong expertise in cardiovascular, renal, inflammatory and metabolic disease research. Within LipidBRIGHT, Maastricht University contributes expertise in lipid biology, vascular pathology, clinical and translational research, and mass-spectrometry-based lipidomics.
​
Research activities are embedded in the Departments of Biochemistry and Pathology and the Maastricht MultiModal Molecular Imaging Institute (M4I), which provides infrastructure for lipidomics, spatial imaging, and multi-omics data integration. Maastricht University has extensive experience in European collaborative research and doctoral training networks, including coordination of previous MSCA Doctoral Networks.
​
Project leaders:
PD Dr. Heidi Noels (Coordinator)
Prof. Dr. Joachim Jankowski (Co-Coordinator)
Prof. Dr. Maarten Honing
Katholieke Universiteit Leuven
(Leuven, Belgium)
Katholieke Universiteit Leuven contributes expertise in lipid metabolism, lipidomics, and translational cancer research. Within LipidBRIGHT, research is centred in the Laboratory of Lipid Metabolism and Cancer, embedded in the Department of Oncology.
​
KU Leuven provides experience in clinical lipidomics, biomarker development, and integration of omics data with patient studies, including involvement in clinical trials addressing lipid-targeting strategies in cancer.
​
Project leader:
Prof. Dr. Johannes V. Swinnen
Universiteit Hasselt
(Hasselt, Belgium)
​
Universiteit Hasselt contributes expertise in immunology and chronic inflammatory diseases, with a particular focus on neuro-inflammation. Research is embedded in the Department of Immunology at the Biomedical Research Institute.
​
The institution provides advanced cellular, ex vivo and in vivo models to investigate lipid-driven immune dysregulation and inflammatory mechanisms, supporting LipidBRIGHT’s mechanistic research objectives.
​
Project leader:
Prof. Dr. Jerome Hendriks
Universitätsklinikum Jena
(Jena, Germany)
https://www.uniklinikum-jena.de
​
Universitätsklinikum Jena is a university hospital with strong clinical and translational research activities in cardiovascular disease. Within LipidBRIGHT, the Department of Internal Medicine I, Division of Cardiology, contributes expertise in heart failure, cardiovascular cohorts, and patient-based research.
​
The institution provides access to well-characterised clinical cohorts and biobanks, enabling translational lipidomics and mechanistic studies in cardiovascular disease.
​
Project leader:
Prof. Dr. Christian Schulze
Institut National de la Santé
et de la Recherche Médicale (France)
​
INSERM is France’s national institute for health and medical research. Within LipidBRIGHT, INSERM contributes expertise in cardiovascular disease, inflammation, and lipid mediator biology.
​
Research activities are centred in the Research Unit DCAC – Acute and Chronic Cardiovascular Deficiency, focusing on lipid-driven mechanisms of vascular dysfunction and inflammation, supported by advanced mass-spectrometry methods for lipid mediator analysis.
​
Project leader:
Prof. Dr. Magnus Bäck
Universiteit Utrecht
(Utrecht, The Netherlands)
​
Universiteit Utrecht contributes expertise in pharmacology, immunology, and nutritional sciences. Within LipidBRIGHT, research is embedded in the Department of Pharmacology at the Utrecht Institute for Pharmaceutical Sciences.
​
The institution focuses on lipid-mediated immune modulation and nutritional lipid interventions, supporting mechanistic and translational studies in inflammatory disease.
​
Project leaders:
Ass. Prof. Dr. Linette Willemsen
Prof. Dr. Johan Garssen
Universität Bern
(Bern, Switzerland)
​
Universität Bern participates in LipidBRIGHT as a beneficiary under a Swiss government funding guarantee. Research is embedded in the Division of Angiology at the Swiss Cardiovascular Center, Inselspital.
​
The institution contributes expertise in vascular inflammation, lipid-driven vascular pathology, and targeted therapeutic strategies, including lipid-based interventions and nanoparticle approaches.
​
Project leader:
Prof. Dr. Yvonne Döring
SciCross
(Skövde, Sweden)
​
SciCross is a data-science company specialised in bioinformatics, machine learning and artificial intelligence for translational biomedical research. Within LipidBRIGHT, SciCross supports multi-omics data integration, disease modelling, and biomarker discovery.
​
SciCross contributes to both research and training, providing doctoral candidates with structured exposure to non-academic, AI-driven research environments.
​
Project leader:
Dr. Pierre Donnes
RD-Néphrologie SAS
(Montpellier, France)
​
RD-Néphrologie SAS is a biomedical research company specialised in nephrology and cardiorenal disease. Within LipidBRIGHT, the company contributes expertise in chronic kidney disease, vascular pathology, and lipid-targeting preventive strategies.
​
RD-Néphrologie supports translational and industry-oriented research activities, linking experimental models with clinical relevance.
​
Project leader:
Prof. Dr. Angel Argiles